{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:45:22Z","timestamp":1781793922018,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jval.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:37:54Z","timestamp":1670585874000},"page":"567-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised"],"prefix":"10.1016","volume":"26","author":[{"given":"Sarah","family":"Acaster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Mukuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Rowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Brazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Quittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Sosnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2022.12.002_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2006.05.008","article-title":"A\u00a0survey of newborn screening for cystic fibrosis in Europe","volume":"6","author":"Southern","year":"2007","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jval.2022.12.002_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10059","key":"10.1016\/j.jval.2022.12.002_bib3","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jval.2022.12.002_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jcf.2017.11.019","article-title":"Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: a longitudinal study using UK patient registry data","volume":"17","author":"Keogh","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jval.2022.12.002_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jpainsymman.2007.06.005","article-title":"Self-reported physical and psychological symptom burden in adults with cystic fibrosis","volume":"35","author":"Sawicki","year":"2008","journal-title":"J\u00a0Pain Symptom Manag"},{"issue":"12","key":"10.1016\/j.jval.2022.12.002_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.jval.2022.12.002_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1183\/09031936.00224911","article-title":"Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study","volume":"41","author":"Bradley","year":"2013","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jval.2022.12.002_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1569-1993(03)00093-6","article-title":"Quality of life in cystic fibrosis: the impact of gender, general health perceptions and disease severity","volume":"2","author":"Gee","year":"2003","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jval.2022.12.002_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1378\/chest.09-0345","article-title":"Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States","volume":"137","author":"Quittner","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jval.2022.12.002_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1513\/AnnalsATS.201408-393OC","article-title":"A\u00a0systematic review of factors associated with health-related quality of life in adolescents and adults with cystic fibrosis","volume":"12","author":"Habib","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.jval.2022.12.002_bib12","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jval.2022.12.002_bib13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11136-011-0036-z","article-title":"Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample","volume":"21","author":"Quittner","year":"2012","journal-title":"Qual Life Res"},{"issue":"6","key":"10.1016\/j.jval.2022.12.002_bib14","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.jval.2022.12.002_bib15","series-title":"Measuring and Valuing Health for Economic Evaluation","author":"Brazier","year":"2017"},{"issue":"2","key":"10.1016\/j.jval.2022.12.002_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jval.2022.12.002_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41687-020-00222-9","article-title":"EQ-5D: a plea for accurate nomenclature","volume":"4","author":"Brooks","year":"2020","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"11","key":"10.1016\/j.jval.2022.12.002_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"10","key":"10.1016\/j.jval.2022.12.002_bib19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2022.12.002_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12955-016-0465-z","article-title":"Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis","volume":"14","author":"Solem","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2022.12.002_bib21","series-title":"Self-Reported Population Health: an International Perspective Based on EQ-5D","article-title":"Population norms for the EQ-5D","author":"Janssen","year":"2014"},{"issue":"2","key":"10.1016\/j.jval.2022.12.002_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2018.08.001","article-title":"Correspondence between symptoms and preference-based health status measures in the STOP study","volume":"18","author":"Gold","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jval.2022.12.002_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12955-015-0224-6","article-title":"Mapping the EQ-5D index from the Cystic Fibrosis Questionnaire-Revised using multiple modelling approaches","volume":"13","author":"Acaster","year":"2015","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.jval.2022.12.002_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J\u00a0Health Econ"},{"issue":"11","key":"10.1016\/j.jval.2022.12.002_bib25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0895-4356(98)00103-6","article-title":"Deriving a preference-based single index from the UK SF-36 Health Survey","volume":"51","author":"Brazier","year":"1998","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"32","key":"10.1016\/j.jval.2022.12.002_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16320","article-title":"Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome)","volume":"16","author":"Brazier","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2022.12.002_bib27","series-title":"(1997-2012) RUMM2030: Rasch Unidimensional Models for Measurement","author":"Andrich","year":"2010"},{"key":"10.1016\/j.jval.2022.12.002_bib28","series-title":"Stata Statistical Software: Release 14","year":"2015"},{"issue":"21","key":"10.1016\/j.jval.2022.12.002_bib29","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2022.12.002_bib30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.jval.2022.12.002_bib31","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jval.2022.12.002_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","article-title":"Patient-reported respiratory symptoms in cystic fibrosis","volume":"8","author":"Goss","year":"2009","journal-title":"J\u00a0Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jval.2022.12.002_bib33","doi-asserted-by":"crossref","first-page":"rm4","DOI":"10.1187\/cbe.16-04-0148","article-title":"Rasch analysis for instrument development: why, when, and how?","volume":"15","author":"Boone","year":"2016","journal-title":"CBE Life Sci Educ"},{"issue":"2","key":"10.1016\/j.jval.2022.12.002_bib34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11136-008-9428-0","article-title":"The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis","volume":"18","author":"Young","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2022.12.002_bib35","first-page":"A4681","article-title":"Substrate utilisation during exercise in children with CF and healthy controls - the impact of CFTR modulator therapy","volume":"201","author":"Selvadurai","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jval.2022.12.002_bib36","series-title":"Economic Evaluation in Health Care: Merging Theory With Practice","author":"Drummond","year":"2001"},{"issue":"1","key":"10.1016\/j.jval.2022.12.002_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","article-title":"Measurement of health state utilities for economic appraisal: a review","volume":"5","author":"Torrance","year":"1986","journal-title":"J\u00a0Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2022.12.002_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/hec.1596","article-title":"A\u00a0uniform time trade off method for states better and worse than dead: feasibility study of the \u2018lead time\u2019 approach","volume":"20","author":"Devlin","year":"2011","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2022.12.002_bib39","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2022.12.002_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jval.2022.12.002_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","article-title":"Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets","volume":"36","author":"Mulhern","year":"2018","journal-title":"Pharmacoecon"},{"issue":"8","key":"10.1016\/j.jval.2022.12.002_bib42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","article-title":"United States valuation of EQ-5D-5L health states using an international protocol","volume":"22","author":"Pickard","year":"2019","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2022.12.002_bib43","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/hec.3950","article-title":"U.K. utility weights for the EORTC QLU-C10D","volume":"28","author":"Norman","year":"2019","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2022.12.002_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.jval.2022.12.002_bib45","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.12.002_bib46","doi-asserted-by":"crossref","first-page":"S689","DOI":"10.1016\/j.jval.2020.08.1732","article-title":"PR1 comparison of the psychometric performance of a new condition-specific preference-based measure derived from the CFQ-R (CFQ-R-8D) to EQ-5D-3L and SF-6D to evaluate health-related quality-of-life (HRQOL) in people with cystic fibrosis (CF)","volume":"23","author":"Mukuria","year":"2020","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:44Z","timestamp":1761096764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522047532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1098301522047532"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.12.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}